Literature DB >> 15786518

Resveratrol and breast cancer chemoprevention: molecular mechanisms.

Ludovic Le Corre1, N Chalabi, L Delort, Yves-Jean Bignon, D J Bernard-Gallon.   

Abstract

Despite years of intensive research, breast cancer remains a major cause of death among women. New strategies to combat breast cancer are being developed, one of the most exciting of which is the use of chemopreventive agents. Resveratrol (RES) is a polyphenolic compound found in plants that seems to have a wide spectrum of biological activity. RES has been shown to afford protection against several types of cancer. This review summarizes the chemopreventive effects of RES at the three major stages of breast carcinogenesis: initiation, promotion, and progression. It has anti-oxidant and anti-inflammatory properties, and may induce apoptosis as well as modulate cell cycle and estrogen receptor function in breast cancer cell lines. Although RES has shown remarkable promise as a potent chemopreventive agent in breast cancer, further studies are needed to etablish its usefulness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15786518     DOI: 10.1002/mnfr.200400094

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  48 in total

1.  Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.

Authors:  Anurima Majumder; Lakshmanan Govindasamy; Andrew Magis; Róbert Kiss; Tímea Polgár; Rebekah Baskin; Robert W Allan; Mavis Agbandje-McKenna; Gary W Reuther; György M Keseru; Kirpal S Bisht; Peter P Sayeski
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

Review 2.  Phytochemicals in the oncology setting.

Authors:  Catherine E Ulbricht; Wendy Chao
Journal:  Curr Treat Options Oncol       Date:  2010-12

3.  The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.

Authors:  Annet Kirabo; Jennifer Embury; Róbert Kiss; Tímea Polgár; Meghanath Gali; Anurima Majumder; Kirpal S Bisht; Christopher R Cogle; György M Keseru; Peter P Sayeski
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

4.  The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.

Authors:  Annet Kirabo; Sung O Park; Anurima Majumder; Meghanath Gali; Mary K Reinhard; Heather L Wamsley; Zhizhuang Joe Zhao; Christopher R Cogle; Kirpal S Bisht; György M Keserü; Peter P Sayeski
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

5.  Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Hee Jeong Kim; Eliot M Rosen; Sivanesan Dakshanamurthy; Riccardo Rondanin; Riccardo Baruchello; Giuseppina Grisolia; Simoni Daniele; Insoo Bae
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

6.  Preferential induction of cytochrome P450 1A1 over cytochrome P450 1B1 in human breast epithelial cells following exposure to quercetin.

Authors:  Sarah M Mense; Jaimeet Chhabra; Hari K Bhat
Journal:  J Steroid Biochem Mol Biol       Date:  2008-03-29       Impact factor: 4.292

Review 7.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 8.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors α and β in breast cancer cells.

Authors:  Amruta Ronghe; Anwesha Chatterjee; Bhupendra Singh; Prasad Dandawate; Fatma Abdalla; Nimee K Bhat; Subhash Padhye; Hari K Bhat
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-09       Impact factor: 4.219

10.  Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor.

Authors:  Mi Young Kim; Eileen M Woo; Yee Ting Esther Chong; Daria R Homenko; W Lee Kraus
Journal:  Mol Endocrinol       Date:  2006-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.